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Sudden cardiac death remains the global burden. The most common associated arrhythmia is ventricular
ﬁbrillation. From current guidelines, deﬁbrillation is the most critical step to rescue the cardiac arrest
victims. Internal deﬁbrillators were invented for prompt treating the ventricular arrhythmia. The MADIT
trial the benchmark randomized controlled trial that demonstrated the efﬁcacy of deﬁbrillators for
sudden death protection and not only that MADIT-RIT which addresses the issue of inappropriate
therapy with ICD and MADIT-CRT which highlights the importance of biventricular pacing in patients
with cardiomyopathy with mild heart failure symptoms. Hereby, we review the articles the MADIT trials.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
2. MADIT trial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
3. MADIT-II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
4. MADIT-CRT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
5. MADIT-RIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
6. Future direction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
Conﬂict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3371. Introduction
Sudden cardiac death (SCD) has remained unsolved global
problem. The actual rate of sudden death is still incompletely
deﬁned, and varies among the studies; however, the most
widely cited estimation is in the range of 300,000–350,000 cases
annually [1].
In recent prospective studies using multiple sources in the
United States, Netherlands, Ireland, and China [2–4], SCD rates
range from 50 to 100 per 100,000 in the general population [3].
Regional incidence of SCD has periodically been reported.
The incidence of SCD in Europe is around one per 1000 population
per year [2], similar to those in US. In Asia, data from Japant Rhythm Society. Published by Els
arrow Hospital,
ing, MI 48912, USA.
prasertkul).showed a similar incidence to that seen in the US and Europe, with
the annual rate estimated to be 1–2 per 1000 population per year
[5]. In China, from a project involving four major cities the annual
incidence of SCD was estimated to be 0.42 per 1000 population [4].
In Hong Kong, the SCD incidence rate was found to be only 0.018
per 1000 population [3].
Malignant ventricular arrhythmia is the most commonly
rhythm abnormality (80%) in patients with cardiac arrest [6,7].
Other bradyarrhythmias were also found associated with sudden
death [6–10]. Prompt recognition and cardiopulmonary resuscita-
tion save life in cardiac arrest patients, and external deﬁbrilla-
tion is the most critical step to treat ventricular arrhythmia.
This scheme has been adopted to the national guideline for
patients who suffer from cardiac arrest. Due to success in treating
ventricular arrhythmia, the implantable automatic deﬁbrillators
(ICD) were introduced for treating ventricular arrhythmia by
Mirowki et al. [11]. Winkle et al. and Fogoros et al. have ﬁrst
shown the efﬁcacy of ICDs in treating ventricular arrhythmiaevier B.V. All rights reserved.
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Apart from SCD protection, there have been subsequent studies
regarding the utilities of ICDs. In this review, we discuss the
prototype randomized controlled trials (MADIT trials) that studied
the efﬁcacy of ICDs and its applications.2. MADIT trial
In early 1980, the Multicenter Post-infarction Research Group
reported the declination of left ventricular function associated
with the increase in the one-year cardiac mortality, with expo-
nential relationship when ejection fraction less than 0.35 [14].
Non-sustained ventricular tachycardia, ventricular dysfunction
and coronary artery disease were found to increased risk of
sudden death. Buxton et al. have shown left ventricular ejection
fraction is the strongest predictor for sudden cardiac death [15].
They have also shown that inducible VT signiﬁcantly predicts the
risk of death in patients with coronary artery disease [15]. Bigger
et al. conﬁrmed that unsustained ventricular tachycardia was
associated with 30% two-year mortality rate in patient with
coronary artery disease [16]. Antiarrhythmic drugs have been
widely used to treat for non-sustained ventricular tachycardia;
however, the survival beneﬁt from antiarrhythmic therapy has not
been proven [17]. Previous ﬁndings frommajor trial suggested that
antiarrhythmic drugs class IC increased cardiac mortality in
patients with coronary artery disease [18]. From these outcomes,
the need for ICD trials was heightened to address the efﬁcacy of
sudden death prevention in these high-risk patients. The Multi-
center Automatic Deﬁbrillator Implantation Trial (MADIT or
MADIT-I trial) was initiated in 1991 [19,20]. This was the ﬁrst trial
that demonstrated the role of ICD for primary prevention of SCD in
asymptomatic patients with ischemic cardiomyopathy.
MADIT trial enrolled 196 adult patients with prior myocardial
infarction more than 3 weeks (Q wave or elevated cardiac
enzyme), with non-sustained ventricular tachycardia (a run of
3–30 of ventricular ectopic beats with a rate more than 120 beats
per minute), with left ventricular ejection fraction less than or
equal to 0.35, and NYHA class I–III. The trial excluded patients with
coronary artery bypass grafting within 2 months or coronary
angioplasty within 3 months prior to the study. Wilber et al. had
found patients with coronary artery disease with abnormal ven-
tricular function had 50% incidence of sudden death in 2 years if
ventricular arrhythmia were inducible, and the inducibility of
ventricular arrhythmia was a signiﬁcant independent predictor
for sudden death [21]. From this study, the inducibility of ventri-
cular arrhythmia was included in eligibility criteria. The primary
end-point was the all-cause mortality. The study compared the
primary outcomes in patients with ICD versus conventional therapy.
Termination of trial was initiated when 51 deaths were reported,
and the efﬁcacy boundary of sequential design was crossed.
Major outcomes from MADIT trial suggested that the risk of
death in deﬁbrillator group was signiﬁcantly less than conventional-
therapy group with hazard ratio of 0.46. This over-all mortality
reduction was contributed from reduction in cardiac death. However,
there was no explanation why more patients with a deﬁbrillator in
the study died from non-arrhythmia causes than patients without a
deﬁbrillator. This was postulated from investigators that it might
because of misclassiﬁcation of the cause of death [20]. From this trial,
ICD was approved for indication for primary prevention in high-risk
patients.
This trial had been criticized in several aspects, since it was
published in 1996. Moreover, another similar cohort, The Multi-
center Unsustained Tachycardia Trial (MUSTT), was often com-
pared to MADIT [22]. One of the important differences was that
beta-blockers were used in 16% in patients in MADIT trial, ascompared to 40% in MUSTT trial. The imbalance of beta-blocker
use favored ICD-treated patients in MADIT trial (15% control group,
26% ICD group), as compared with MUSTT, which favored the
control group (51% control group, 34% ICD group). However, both
trials showed the similarity of the outcomes in that the mortality
reduction was observed particularly in ICD-treated patients.
The absence of untreated group in MADIT trial was also discussed
that this could be attributed to harm caused by antiarrhythmic
drug in conventional group [23]. The “conventional group” was
also questioned. This group was suggested to conﬁne with non-
antiarrhythmic therapy, and in fact, there was marked variability
in management in this group—the choice of treatment was on
physician's decision. The other important limitation is the repro-
ducibility of ventricular arrhythmia. Senges et al. found that non-
sustained ventricular tachycardia on Holter monitor in patients
fulﬁlling MADIT criteria had limited clinical value in patient
selection for programmed ventricular stimulation [24].3. MADIT-II
Electrophysiological testing has been used to identify who is at
risk of sudden cardiac arrest, but its utility in patients with
coronary artery disease and left ventricular dysfunction remains
uncertain. In addition, electrophysiological testing in MADIT trial
could possibly select the high-risk patients who less likely to be
respond to antiarrhythmic drug therapy [25]. In addition, two-year
mortality rate is in the range of 20% in patients with coronary
artery disease with ejection fraction less than or equal to 0.30,
with the optimal therapies [26]. From above reasons, MADIT-II did
not include electrophysiologic testing for selection criteria. Moss
et al. initiated MADIT-II in 1999 [27]. This trial enrolled 1232
patients with prior myocardial infarction more than 4 weeks (Q
wave or elevated cardiac enzyme), with left ventricular ejection
fraction less than or equal to 0.30, and NYHA class I–III. The trial
excluded patients with coronary artery bypass grafting or coronary
angioplasty within 3 months prior to the study. Repetitive ven-
tricular ectopy was eliminated from inclusion criteria after the
study began because almost all eligible patients had such arrhyth-
mia. Primary outcome was death from any causes.
Major outcomes from MADIT-II trial suggested that, once again,
the risk of death in deﬁbrillator group was signiﬁcantly less than
conventional-therapy group with hazard ratio of 0.69. In this trial,
the major drawback was corrected. The medication use remained
balanced between ICD patients, and conventional therapy patients.
The size of study population was greater in the latter study.
However, hazard ratio of rate of death in the latter trial was
higher than the former one. This was mentioned to be due to the
lower cutoff of ejection fraction, more vigorous medication [28].
Interestingly, the rate of heart failure hospitalization was unex-
pectedly high in ICD patients (20% versus 15%). The explanation
was uncertain, but was thought to be due to (1) multiple shocks
leading to myocardial injury; (2) higher incidence of heart failure
progression in ICD patients with longer life span; (3) right
ventricular pacing adversely impacting ventricular synchrony.
MADIT-II trial was designed without risk stratiﬁcation, target-
ing broad range of population. Several subgroup analyses from
MADIT-II have been published after the main trial. The advantage
of ICD in lowering mortality risk depends on time since the most
recent myocardial infarction [29]. The longer after myocardial
infarction is associated with the greater mortality reduction. ICD
was equally beneﬁcial in diabetic and non-diabetic patients [30].
In addition, age seems not to impact on the mortality beneﬁt from
ICD, even though elderly patients, older than 75 years old, were
marginally beneﬁtted from ICD [31]. Dhar et al. also showed the
QRS duration associated with SCD in non-ICD patients; however, it
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patients [32]. However, patients with advanced renal dysfunction
do not received the protective effect from ICD [33].4. MADIT-CRT
The heart failure event in the MADIT-II trial led to the MADIT-
CRT. The similar outcomes were found in SCD-HeFT and DEFINITE
trials [34]. From prior study, Bristow et al. demonstrated the
mortality reduction from CRT-D and CRT-P as compared to medical
therapy alone. However the patients included in this trial were in
NYHA class III and IV [35]. This trial was designed in 2005 aiming
at patients with NYHA class I and II for preventive purposes [36].
One thousand eight hundred patients were included (consist-
ing of ischemic or non-ischemic cardiomyopathy, a QRS duration
more than or equal to 130 ms, NYHA class I, II, ejection fraction
less than or equal to 30%). These patients were randomized to ICD
plus CRT, or ICD alone. Due to the adverse effect of right
ventricular pacing, a lower rate limit was set at 40 beats per
minute both groups. Primary outcome was assessed for composite
of death or non-fatal heart failure.
The primary outcome occurred 17.2% in ICD plus CRT patients
as compared to 25.3% in ICD only patients, with hazard ratio of
0.66. This risk reduction was attributed by 41% reduction in the
risk of heart failure. The hazard ratios for primary end points in
ischemic and non-ischemic cardiomyopathy patients were similar.
In subgroup analyses, it suggested that CRT-D had equal mortality
beneﬁt in each subgroup (regardless of ejection fraction,
age, LVESV, LVEDV, NYHA class). Nevertheless, women had greater
mortality reduction than men, and this CRT-D will reduce
mortality only in patients with QRS width more than or equal to
150 ms. This major outcome seemed to be conﬁrmed with
REVERSE trial [37].5. MADIT-RIT
Growing number of ICD trials lead to the popularity of ICD
implantation. Inappropriate therapy from ICD has become a
problem in clinical practice. Supraventricular tachyarrhythmia
remained the most common rhythm causing inappropriate ther-
apy despite the proper ICD programming. Major adverse conse-
quences' following inappropriate therapy includes pain, anxiety, a
poor quality of life, proarrhythmia [38,39]. In addition, this could
trigger fatal arrhythmia. Even though, dual-chamber ICD's are
implanted twice as frequently as single chamber ICD's due to
proper rhythm detection and differentiation, no randomized con-
trolled trial has shown that proper ICD programming for reducing
inappropriate therapy would affect the clinical outcomes. This trial
was initiated in 2012 to determine appropriate ICD programing
[40].
This trial included 1500 patients, who met the ICD criteria for
primary prevention (non-ischemic, ischemic, dual chamber ICD or
CRT-D). The patients were randomized to 3 arms: (1) conventional
therapy: Zone 1(VT) 170 bpm, 2.5 s delay, Zone 2 (VF) 200 bpm, 1 s
delay; (2) high rate therapy: Zone 1(VT) 170 bpm, monitor only,
Zone 2 (VF) 200 bpm, 2.5 s delay; (3) long delay therapy: Zone 1
(VT) 170 bpm, 60 s delay, Zone 2 (VT) 200 bpm, 12 s delay, Zone 3
250 bpm, 2.5 s delay. Primary outcomes were assessed as the ﬁrst
occurrence of inappropriate therapy (ATPs or shocks), The sec-
ondary end points were assessed as death from any cause and the
ﬁrst episode of syncope.
Primary outcomes were found as high-rate group and long-
delay group had signiﬁcantly greater risk for device therapy
than conventional therapy with 79% and 76% risk reductionrespectively. Mortality reduction also was shown in high-rate
group and long-delay group with 55% and 44% risk reduction.
With previous concern of syncope with delay treatment, the
similar rate of syncope episodes was demonstrated in each
patient group. With lower rate of inappropriate therapy, it was
suggested that ventricular tachyarrhythmia detected by ICD
could possibly terminated spontaneously without unnecessary
treatment. However, the reason for reducing mortality in the trial
remains unclear.
The MADIT-RIT study enrolled only primary-prevention patients.
An earlier study, PainFREE Rx II, explored the over-all rates of
inappropriate therapy in both primary and secondary prevention
patients [41]. Both groups had a 15% rate of inappropriate therapy,
but these were slightly more common in primary-prevention
patients. Of all the arrhythmic events detected and treated by
the ICD, 46% led to inappropriate therapy in primary-prevention
patients compared to 34% in secondary-prevention patients. With
secondary-prevention patients, clinicians have arrhythmic history
to help guide programming decisions.
The MADIT-RIT study found that high-rate and delayed-therapy
were both effective in reducing inappropriate shock and mortality
compared to conventional therapy. Since they are both effective,
the simpler one should take precedence. Programming a cutoff
rate of 200 bpm is very straightforward (and much easier to
program than delayed therapy) and MADIT-RIT found it reduced
both inappropriate therapy and mortality rates. Program a high VF
cutoff (for example, 200 bpm) and delay the onset of the therapy
— MADIT-RIT shows that this saves lives.6. Future direction
Although “MADIT” studies have proven beneﬁts from ICDs, no
randomized controlled have been created for the certain patient
subgroups. It remains unclear whether all patients with similar
proﬁles (to inclusion criteria) in cohorts would gain similar beneﬁt
from ICDs. In addition, results from previous studies for risk
stratiﬁcation have not been consistent, and could not be applicable
reliably to general population or to ICD candidates. Some ques-
tions, which remain unanswered with “MADIT” studies, were
whether the patients with advanced heart failure and narrow
QRS complex, do they beneﬁt from biventricular pacing? Two
prospectively designed, yet moderately large, studies in patients
with advanced HF and normal QRS complex have been completed,
the ReThinQ [42] and ESTEEM-CRT [43] trials; both studies missed
the primary end-point and turned out to be negative. What about
patients with moderate LV dysfunction and need for RV pacing?
HOBIPACE [44] and PAVE [45] studies show that patients with
preexisting mild to moderate left ventricular dysfunction and an
indication for standard pacing have improved left ventricular
systolic function, exercise capacity, and quality of life after biven-
tricular pacing compared with right ventricular apical pacing.
These results suggest that biventricular pacing may be a feasible
option for permanent pacing in the majority of patients who have
normal left ventricular systolic function and that it may attenuate
the adverse effects of conventional right ventricular apical pacing
on left ventricular systolic function. This hypothesis has been
recently tested in the PACE trial [46]. The study was a double-
blinded, multicenter study, in which 177 patients were assigned to
either biventricular pacing (89 patients) or right ventricular apical
pacing (88 patients). The PACE study showed that mean LVEF
declined by almost 7 percentage points (from 61.576.6 to
54.879.1) in the ﬁrst year of right ventricular apical pacing in
patients with a normal ejection fraction. There are several limita-
tions of this study: the sample was small, and the study was
not powered to detect signiﬁcant differences in clinical events.
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pacemakers are potential concerns. Randomized trials with longer
follow-up periods, larger samples, and sufﬁcient power to evaluate
clinical outcomes between these two pacing strategies are war-
ranted. Even though, the cost of ICDs has come down, ﬁnancial
restrain has not yet been resolved in the new healthcare reform.
These questions would be important challenges and would prob-
ably be answered in the future trial with the least cost and the
most survival implication in the clinical practice.Conﬂict of interest
None.
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